Status: Not yet recruiting
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for downstaging primary stage IVB oral squamous cell carcinoma or HPV16-negative oropharyngeal squamous cell carcinoma.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Huashan HospitalUpdated: Sep 28, 2026
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance status: 0-1; [+8]
Unresolved toxicity of grade 2 or higher due to prior anticancer therapy; [+11]